Wu Hsued Hwa, Chen Chueh Tan, Lin Yi-Ling, Lee Sho Tone
Division of Infectious Diseases, Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan, ROC.
Vaccine. 2004 Jan 26;22(5-6):793-800. doi: 10.1016/j.vaccine.2003.02.001.
The envelope (E) gene of Japanese encephalitis virus (JEV) plays a major protective role against JEV infection. In order to locate the part of E gene that is responsible for this protection, an N-terminal fragment EA (nucleotide number 933-1877 bp of JEV genome) and a C-terminal fragment EB (nucleotide number 1851-2330 bp of JEV genome) from E gene were prepared. Both of these fragments were used in the form of recombinant proteins (rEA and rEB) and plasmid DNA (pEA, pM15EA and pEB) for immunizations. Recombinant EA protein (rEA) was previously found to be non-protective because it was expressed in an insoluble form. Plasmid EA (pEA) was also found to be non-protective unless it is preceded by a 15 mer signal peptide derived from the very C-terminal of the membrane gene (M) of JEV to form pM15EA plasmid indicating the importance of the signal peptide in the expression of EA immunogenicity. Although pM15EA and pEB are both immunogenic and protective against JEV lethal infection, the protection by both fragments however is not optimal. Even when pM15EA and pEB were used together for immunization, maximum protection as those induced by control vaccine was not achieved. However, if individual fragments (EA or EB) were used in a DNA priming-protein boosting or protein priming-DNA boosting strategy, high levels of protection were achieved by both fragments. This was especially true for EA fragment where the level of protection against JEV lethal infection was equal to that induced by commercially available vaccine alone. The protection correlated very well with the neutralizing antibody titers and the T helper cell involved in this process in mainly the Th1 type.
日本脑炎病毒(JEV)的包膜(E)基因在抵抗JEV感染方面发挥着主要保护作用。为了确定E基因中负责这种保护作用的部分,制备了来自E基因的N端片段EA(JEV基因组核苷酸编号933 - 1877 bp)和C端片段EB(JEV基因组核苷酸编号1851 - 2330 bp)。这两个片段均以重组蛋白(rEA和rEB)和质粒DNA(pEA、pM15EA和pEB)的形式用于免疫接种。先前发现重组EA蛋白(rEA)无保护作用,因为它以不溶性形式表达。还发现质粒EA(pEA)无保护作用,除非其前面有一个源自JEV膜基因(M)最C端的15聚体信号肽,从而形成pM15EA质粒,这表明信号肽在EA免疫原性表达中的重要性。尽管pM15EA和pEB均具有免疫原性且对JEV致死性感染具有保护作用,但两个片段的保护作用都不是最佳的。即使将pM15EA和pEB一起用于免疫接种,也未达到对照疫苗诱导的最大保护效果。然而,如果将单个片段(EA或EB)用于DNA初免 - 蛋白加强或蛋白初免 - DNA加强策略,则两个片段均能实现高水平的保护。对于EA片段尤其如此,其对JEV致死性感染的保护水平与单独使用市售疫苗诱导的保护水平相当。这种保护作用与中和抗体滴度以及主要参与此过程的Th1型辅助性T细胞密切相关。